Pfizer Inc. (PFE)
Pfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Pfizer (PFE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Pfizer (PFE) Q1 Earnings and Revenues Top Estimates
Pfizer (PFE) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.92 per share a year ago.
Pfizer Posts Better-Than-Expected Revenue, Profit
Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.
Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending
Pfizer posted higher first-quarter revenue but lower profit that was weighed down partially by higher research and development spending.
Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates
The drugmaker has been leaning on recently acquired products to offset a looming patent cliff.
Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth
Pfizer posted first-quarter earnings and revenue that topped estimates and reaffirmed its 2026 outlook, as recently launched and acquired products showed growth. The pharmaceutical giant is looking to longer-term investments in its pipeline, including its recent $10 billion acquisition of the obesity biotech Metsera, to counter waning Covid product sales and declines from older drugs.
Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis
Pfizer on Tuesday reported first-quarter profit above Wall Street estimates, boosted by sustained demand for older drugs such as blood thinner Eliquis.
Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era
Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking.
Pfizer: Why You Should Double Down Into Q1
Pfizer remains a high-conviction, undervalued Strong Buy with a robust pipeline and aggressive growth in oncology and obesity platforms. PFE's 2026 guidance reaffirmation is the key near-term catalyst, with management targeting $59.5–$62.5B revenue and $2.8–$3 EPS despite patent expirations. Onshoring high-margin production and aggressive cost-cutting are central to de-risking LOE headwinds and expanding operating margins through 2027.
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings
Pfizer PFE is set to report its first-quarter 2026 earnings on May 5, before market open. The Zacks Consensus Estimate for sales and earnings for the first quarter is pegged at $13.82 billion and 74 cents per share, respectively.
Ahead of Pfizer (PFE) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Why Pfizer (PFE) Dipped More Than Broader Market Today
Pfizer (PFE) reached $26.48 at the closing of the latest trading day, reflecting a -1.16% change compared to its last close.
